W. Michael Flanagan

9.4k total citations · 4 hit papers
101 papers, 7.6k citations indexed

About

W. Michael Flanagan is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, W. Michael Flanagan has authored 101 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Molecular Biology, 33 papers in Oncology and 16 papers in Epidemiology. Recurrent topics in W. Michael Flanagan's work include RNA Interference and Gene Delivery (21 papers), Advanced biosensing and bioanalysis techniques (20 papers) and Global Cancer Incidence and Screening (14 papers). W. Michael Flanagan is often cited by papers focused on RNA Interference and Gene Delivery (21 papers), Advanced biosensing and bioanalysis techniques (20 papers) and Global Cancer Incidence and Screening (14 papers). W. Michael Flanagan collaborates with scholars based in United States, Canada and Australia. W. Michael Flanagan's co-authors include Robert H. Crabtree, Jamison L. Nourse, Steve Coats, Richard J. Bram, Blaise Corthésy, Gerald R. Crabtree, James M. Roberts, Richard W. Wagner, Eduardo Firpo and James M. Roberts and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

W. Michael Flanagan

97 papers receiving 7.4k citations

Hit Papers

Nuclear association of a T-cell transcription factor bloc... 1991 2026 2002 2014 1991 1994 1996 1992 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A
    1991 930 citations W. Michael Flanagan et al. profile →
  2. lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin
    1994 805 citations W. Michael Flanagan et al. profile →
  3. Requirement of p27 Kip1 for Restriction Point Control of the Fibroblast Cell Cycle
    1996 610 citations W. Michael Flanagan et al. profile →
  4. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase
    1992 515 citations W. Michael Flanagan et al. profile →

Peers

W. Michael Flanagan
Kapaettu Satyamoorthy India
Wolfgang Tilgen Germany
Jie Xu China
Min Fang China
Ze‐Guang Han China
Martin McIntosh United States
Scott D. Patterson United States
He Huang China
Jae‐Hoon Kim South Korea
Jianfeng Zhou China
Kapaettu Satyamoorthy India
W. Michael Flanagan
Citations per year, relative to W. Michael Flanagan W. Michael Flanagan (= 1×) peers Kapaettu Satyamoorthy

Countries citing papers authored by W. Michael Flanagan

Since Specialization
Citations

This map shows the geographic impact of W. Michael Flanagan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Michael Flanagan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Michael Flanagan more than expected).

Fields of papers citing papers by W. Michael Flanagan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Michael Flanagan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Michael Flanagan. The network helps show where W. Michael Flanagan may publish in the future.

Co-authorship network of co-authors of W. Michael Flanagan

This figure shows the co-authorship network connecting the top 25 collaborators of W. Michael Flanagan. A scholar is included among the top collaborators of W. Michael Flanagan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Michael Flanagan. W. Michael Flanagan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Flanagan, W. Michael, et al.. (2025). Factors Influencing Mental Health Outcomes Amongst Senescent County Residents. International Journal of Environmental Research and Public Health. 22(3). 451–451. 1 indexed citations
2.
Tolaney, Sara M., T. Khanh, Joseph P. Eder, et al.. (2020). A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors. Clinical Cancer Research. 26(21). 5588–5597. 15 indexed citations
3.
Cancilla, Mark T., Jing Kang, Samnang Tep, et al.. (2019). Modeling the Kinetics of Lipid-Nanoparticle- Mediated Delivery of Multiple siRNAs to Evaluate the Effect on Competition for Ago2. Molecular Therapy — Nucleic Acids. 16. 367–377. 12 indexed citations
4.
Evans, William S., W. Michael Flanagan, Cindy L. Gauvreau, et al.. (2018). MA18.03 How in the Real World Are Lung Cancer Patients Treated? The Ontario, Canada Experience. Journal of Thoracic Oncology. 13(10). S419–S419. 2 indexed citations
5.
Hennessy, Deirdre, et al.. (2017). Development of a population-based microsimulation model of body mass index.. PubMed. 28(6). 20–30. 2 indexed citations
6.
Gauvreau, Cindy L., S. Memon, W. Michael Flanagan, et al.. (2017). The OncoSim Model: Development and Use for Better Decision-Making in Canadian Cancer Control. Current Oncology. 24(6). 401–406. 30 indexed citations
7.
8.
Sharif, Behnam, Rochelle Garner, Claudia Sanmartin, et al.. (2016). Risk of work loss due to illness or disability in patients with osteoarthritis: a population-based cohort study. Lara D. Veeken. 55(5). 861–868. 39 indexed citations
9.
Flanagan, W. Michael, et al.. (2015). Performance of the cancer risk management model lung cancer screening module.. PubMed. 26(5). 11–8. 17 indexed citations
10.
Hennessy, Deirdre, W. Michael Flanagan, Peter Tanuseputro, et al.. (2015). The Population Health Model (POHEM): an overview of rationale, methods and applications. Population Health Metrics. 13(1). 24–24. 30 indexed citations
11.
Sharif, Behnam, Jacek A. Kopec, Nick Bansback, et al.. (2015). Projecting the direct cost burden of osteoarthritis in Canada using a microsimulation model. Osteoarthritis and Cartilage. 23(10). 1654–1663. 67 indexed citations
12.
Wong, Suzy L, et al.. (2013). Development of a population-based microsimulation mode of physical activity in Canada.. PubMed. 24(10). 11–9. 4 indexed citations
13.
Fucini, Raymond V., et al.. (2012). Adenosine Modification May Be Preferred for Reducing siRNA Immune Stimulation. Nucleic Acid Therapeutics. 22(3). 205–210. 20 indexed citations
14.
Wei, Jie, Jeffrey J. Jones, Jing Kang, et al.. (2011). RNA-Induced Silencing Complex-Bound Small Interfering RNA Is a Determinant of RNA Interference-Mediated Gene Silencing in Mice. Molecular Pharmacology. 79(6). 953–963. 40 indexed citations
15.
Zhao, Lihong, et al.. (2010). Persistence of seed-based activity following segmentation of a microRNA guide strand. RNA. 16(12). 2336–2340. 7 indexed citations
16.
VanderPorten, Erica C., Pietro Taverna, Jennifer N. Hogan, et al.. (2009). The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Molecular Cancer Therapeutics. 8(4). 930–939. 64 indexed citations
17.
Kopec, Jacek A., Eric C. Sayre, W. Michael Flanagan, et al.. (2009). Development of a population-based microsimulation model of osteoarthritis in Canada. Osteoarthritis and Cartilage. 18(3). 303–311. 31 indexed citations
18.
Lenferink, Anne E.G., Dagmar Busse, W. Michael Flanagan, F. Michael Yakes, & Carlos L. Arteaga. (2001). ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.. PubMed. 61(17). 6583–91. 156 indexed citations
19.
Will, B P, et al.. (2001). First do no harm: extending the debate on the provision of preventive tamoxifen. British Journal of Cancer. 85(9). 1280–1288. 14 indexed citations
20.
Flanagan, W. Michael. (1998). Antisense comes of age. Cancer and Metastasis Reviews. 17(2). 169–176. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kapaettu Satyamoorthy Breakdown of academic impact, for papers by Wolfgang Tilgen Breakdown of academic impact, for papers by Jie Xu Breakdown of academic impact, for papers by Min Fang Breakdown of academic impact, for papers by Ze‐Guang Han Breakdown of academic impact, for papers by Martin McIntosh Breakdown of academic impact, for papers by Scott D. Patterson Breakdown of academic impact, for papers by He Huang Breakdown of academic impact, for papers by Jae‐Hoon Kim Breakdown of academic impact, for papers by Jianfeng Zhou
Rankless by CCL
2026